Thanks to its efforts to develop a COVID-19 vaccine, Novavax Inc. was among the companies that saw its stock price skyrocket over the past year and a half, ever since the search for the vaccine originally began.
In this guide, we will cover How to Invest in Novavax stock and discuss the company’s fundamentals in detail.
In This Guide
If you only wish for us to provide quick instructions on how to invest in Novavax stock, then we show you how to do so in the steps below.
Selecting the right broker is half the job when it comes to trading and investing, as it allows users to trade with a suitable broker of their choice.
In the sections below, we review some of the popular brokers that allow users to invest in Novavvax stocks.
eToro is a broker that has been around for almost 15 years, after being founded in 2007. During this time, it has garnered more than 26 million users from all corners of the world.
As an international platform, eToro is also licensed by some of the biggest and most reliable regulatory bodies around the globe, such as the FCA, FINRA, ASIC, and CySEC.
In terms of what it has to offer, we are looking at more than 2,500 trading instruments available (including ETF, shares like Tesla, Apple, etc) for trade and investments, and they are all available 100% commission-free. There are spreads that traders need to pay, but even spreads are quite low and affordable. eToro allows you to purchase fractional shares, which means that you can buy only a part of a single share if you wish to go for an expensive one but do not wish to put down too much money.
Finally, eToro also offers social trading, with its copy-trading feature being a popular feature on the platform. It allows traders to find an expert who trades in the assets they are interested in and then copy their moves instead of trying to figure out what to do themselves.
Sponsored Ad. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.
Capital.com is a platform available in the UK that focuses on trading Contracts For Difference and Spread Betting. You get access to over 3,000 global markets, which is currently accessed by more than 360,000 platform users.
This platform is also heavily regulated by the FCA and CySEC, and the fact that it offers stock CFDs means that you can enter into leverage trades as well.
Margin trading is also supported, naturally, and the platform only requires a minimum deposit of $20. Finally, the platform also features a lot of educational materials, online courses, and other helpful materials.
Sponsored Ad. 75.26% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.
Before making an investment decision, users may want to properly research a stock and the company. In the sections below, we will provide in-depth information on Novavax as a company, along with some historical stock price data.
Novavax is an American biotechnology company based in Gaithersburg, Maryland, and it creates vaccines that are used for preventing serious infectious diseases. Before 2020, the company’s researchers created a number of experimental vaccines, including the ones for Ebola, respiratory syncytial virus, influenza, and a number of others. However, with the COVID-19 pandemic taking over the entire world in mere weeks back in March 2020, the company focused all its efforts on creating a coronavirus vaccine.
The company did not exactly drop everything else, of course, as it did recognize the need to continue making innovative vaccines in other therapeutic areas. Because of that, it has taken steps to ensure that its nanoflu influenza vaccine will continue to evolve.
Novavax has been around for nearly 35 years now, and at that time, its price has reached major heights several times. Around 2016, however, the Novavax share price crashed to under $50, often fluctuating between this level and $20. Things finally started to change significantly for the company again in April 2020, after its decision to start focusing on the COVID vaccine.
Given the amount of fear and rather strict measures that were introduced in order to combat the pandemic and healthcare in the early days, the companies that were focusing their time and resources on finding a vaccine or a cure were extremely popular, and their services were in high demand. Between March 2020 and February 2021, Novavax’s stock price skyrocketed from only $7 to $290.
In 2021, the price saw another correction to $130, which was in mid-May, only to surge to $257 in August, and then crash once again to $145. At the time of writing, it sits at $148.83, after starting another apparent recovery.
Novavax has had some troubles, despite its skyrocketing stock price. While it has been around for decades, it often saw years of annual losses which kept its stock price low, occasionally broken by a price surge such as the one during the COVID pandemic. The company’s struggle to get its vaccine approved is also not helping, neither its stock, revenue, nor reputation as a manufacturer of vaccines.
The company reported a per-share loss of $4.75 and $298 million in sales in its 2nd quarter.
Novavax currently does not offer a dividend yield, which is not too surprising. Biotech companies usually do not see that much cash flow, which is why they often cannot spare the funds to offer in exchange for investors’ support.
Regarding the company’s ESG (Environmental, Social, Governance) rating, its risk rating is deemed high (31.86). Its controversy level is 1. To give you a comparison, 5 is the worst controversy rating a company can have.
As mentioned, Novavax started its work on the vaccine back in 2020, announcing its involvement back in January. Its vaccine, officially named NVX-CoV2373, is meant to establish immunity against SARS-CoV-2. It is a protein subunit vaccine that contains the spike protein of the virus, and the firm released phase 3 trials a year later, in January 2021.
According to the results, its vaccine was 89% efficient against coronavirus, and it provided strong immunity against new variants, many of which have emerged throughout 2021. Later on, in June 2021, it announced that the efficiency has been improved to 90.4%. Of the total of 77 COVID-19 cases among the volunteers of the clinical-stage trial, 14 cases appeared in the group that received the vaccine, while 63 cases emerged in the placebo group.
Now that you know everything you need to know about Novavax stock, you can analyse the information and make a decision on whether or not you wish to invest in the company.
Should you choose to do so, you may want to pick a suitable brokerage that will cater to your investing needs. In the sections below, we will show you how to begin trading with the chosen broker of your choice.
Head over to the homepage of your chosen broker and begin the account set-up process. You will be required to fill in your personal details – including your full name, email address and mobile number. Create a username and password for the platform to continue.
Most popular brokers are regulated – which is why users may be required to verify their accounts. To do this, simply upload proof of ID (a copy of your driver’s license or passport) and proof of address (a copy of a bank statement or utility bill). Once these documents have been uploaded, your broker should verify them in a couple of minutes.
The next step is to deposit funds into your trading account. Most brokers may support 1 or more of the following payment methods:
Choose your preferred payment option and deposit the funds into your account.
Once your account has been funded, proceed to search for Novavax stock on your platform’s search bar. Fill in the amount you want to credit into the trade, and confirm your transaction.
In this guide, we have provided an in-depth review and analysis on the Novavax stock, price, fundamentals and more. Since there is a level of risk involved in every trade, users may want to review and assess their investment decision separately.
If you choose to invest in Novavax, you may want to do so with a suitable broker that can cater to your investing needs.
Novavax is a biotechnology company based in the US that develops vaccines that are used around the world to prevent serious infectious diseases.
As a publicly-traded company, Novavax is owned by its shareholders.
Novavax is an American company based in Gaithersburg, Maryland.
At the time of writing (November 1st, 2021) Novavax’s stock price is $148.83 per share.
Ali is an experienced writer covering the cryptocurrency markets and the blockchain industry. He has 8 years of experience writing about cryptocurrencies, technology, and trading. His work can be found in various high-profiled investment sites including CCN, Capital.com, BeInCrypto, Bitcoinist, and NewsBTC.
Best UK Stock, Forex, CFD, Crypto, Social or Day Trading Platform that meets your needs.
